Protein Structure Report

You have full text access to this OnlineOpen article

Structure of human thioredoxin exhibits a large conformational change

  1. Gareth Hall,
  2. Jonas Emsley*

Article first published online: 26 JUL 2010

DOI: 10.1002/pro.466

Issue

Protein Science

Protein Science

Volume 19, Issue 9, pages 1807–1811, September 2010

Additional Information

How to Cite

Hall, G. and Emsley, J. (2010), Structure of human thioredoxin exhibits a large conformational change. Protein Science, 19: 1807–1811. doi: 10.1002/pro.466

Author Information

  1. Centre for Biomolecular Sciences, School of Pharmacy, University of Nottingham, Nottingham, NG7 2RD, United Kingdom

*Centre for Biomolecular Sciences, School of Pharmacy, University of Nottingham, Nottingham, NG7 2RD, UK

Publication History

  1. Issue published online: 23 AUG 2010
  2. Article first published online: 26 JUL 2010
  3. Manuscript Accepted: 14 JUL 2010
  4. Manuscript Received: 28 JUN 2010

Funded by

  • School of Pharmacy, University of Nottingham (PhD Scholarship)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (227K)

References

  • 1
    Holmgren A ( 1985) Thioredoxin. Annu Rev Biochem 54: 237–271.
  • 2
    Holmgren A ( 1989) Thioredoxin and glutaredoxin systems. J Biol Chem 264: 13963–13966.
  • 3
    Zeller T, Klug G ( 2006) Thioredoxins in bacteria: functions in oxidative stress response and regulation of thioredoxin genes. Naturwissenschaften 93: 259–266.
  • 4
    Powis G, Briehl M, Oblong J ( 1995) Redox signalling and the control of cell growth and death. Pharmacol Ther 68: 149–173.
  • 5
    Hirota K, Matsui M, Murata M, Takashima Y, Cheng FS, Itoh T, Fukuda K, Yodoi J ( 2000) Nucleoredoxin, glutaredoxin, and thioredoxin differentially regulate NF-kappaB, AP-1, and CREB activation in HEK293 cells. Biochem Biophys Res Commun 274: 177–182.
  • 6
    Padovani D, Mulliez E, Fontecave M ( 2001) Activation of class III ribonucleotide reductase by thioredoxin. J Biol Chem 276: 9587–9589.
  • 7
    Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M, Miyazono K, Ichijo H ( 1998) Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. Embo J 17: 2596–2606.
  • 8
    Arner ES, Holmgren A ( 2006) The thioredoxin system in cancer. Semin Cancer Biol 16: 420–426.
  • 9
    Kirkpatrick DL, Kuperus M, Dowdeswell M, Potier N, Donald LJ, Kunkel M, Berggren M, Angulo M, Powis G ( 1998) Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides. Biochem Pharmacol 55: 987–994.
  • 10
    Tonissen KF, Di Trapani G ( 2009) Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy. Mol Nutr Food Res 53: 87–103.
    Direct Link:
  • 11
    Holmgren A, Roberts G ( 1976) Nuclear magnetic resonance studies of redox-induced conformational changes in thioredoxin from Escherichia coli. FEBS Lett 71: 261–265.
  • 12
    Katti SK, LeMaster DM, Eklund H ( 1990) Crystal structure of thioredoxin from Escherichia coli at 1.68 A resolution. J Mol Biol 212: 167–184.
  • 13
    Saarinen M, Gleason FK, Eklund H ( 1995) Crystal structure of thioredoxin-2 from Anabaena. Structure 3: 1097–1108.
  • 14
    Iulek J, Alphey MS, Westrop GD, Coombs GH, Hunter WN ( 2006) High-resolution structure of recombinant Trichomonas vaginalis thioredoxin. Acta Cryst D62: 216–220.
  • 15
    Hall G, Shah M, McEwan PA, Laughton C, Stevens M, Westwell A, Emsley J ( 2006) Structure of Mycobacterium tuberculosis thioredoxin C. Acta Cryst D62: 1453–1457.
  • 16
    Weichsel A, Gasdaska JR, Powis G, Montfort WR ( 1996) Crystal structures of reduced, oxidized, and mutated human thioredoxins: evidence for a regulatory homodimer. Structure 4: 735–751.
  • 17
    Hashemy SI, Holmgren A ( 2008) Regulation of the catalytic activity and structure of human thioredoxin 1 via oxidation and S-nitrosylation of cysteine residues. J Biol Chem 283: 21890–21898.
  • 18
    Nigro P, Dal Piaz F, Gallotta D, De Tommasi N, Belisario MA ( 2008) Inhibition of the thioredoxin system is a basis for the antileukemic potential of 13-hydroxy-15-oxo-zoapatlin. Free Radic Biol Med 45: 875–884.
  • 19
    Watson WH, Pohl J, Montfort WR, Stuchlik O, Reed MS, Powis G, Jones DP ( 2003) Redox potential of human thioredoxin 1 and identification of a second dithiol/disulfide motif. J Biol Chem 278: 33408–33415.
  • 20
    Lennon BW, Williams CH, Jr, Ludwig ML ( 2000) Twists in catalysis: alternating conformations of Escherichia coli thioredoxin reductase. Science 289: 1190–1194.
  • 21
    Qin J, Clore GM, Kennedy WM, Huth JR, Gronenborn AM ( 1995) Solution structure of human thioredoxin in a mixed disulfide intermediate complex with its target peptide from the transcription factor NF kappa B. Structure 3: 289–297.
  • 22
    Leslie AGW ( 1998) MOSFLM v.6.0. Cambridge: MRC Laboratory of Molecular Chemistry.
  • 23
    McCoy AJ, Grosse-Kunstleve RW, Storoni LC, Read RJ ( 2005) Likelihood-enhanced fast translation functions. Acta Cryst D61: 458–464.
  • 24
    Murshudov GN, Vagin AA, Dodson EJ ( 1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Cryst D53: 240–255.
  • 25
    Emsley P, Cowtan K ( 2004) Coot: model-building tools for molecular graphics. Acta Cryst D60: 2126–2132.
View Full Article with Supporting Information (HTML) Get PDF (227K)